Renal impairment is associated with increased risk of mortality in patients with cirrhosis

A retrospective cohort study

Takeji Umemura, MD, PhD\textsuperscript{a, b, \ast}, Satoru Joshiya, MD, PhD\textsuperscript{a, b}, Soichiro Shibata, MD\textsuperscript{a}, Ayumi Sugiura, MD\textsuperscript{a}, Tomoo Yamazaki, MD\textsuperscript{a}, Naoyuki Fujimori, MD, PhD\textsuperscript{a}, Akihiro Matsumoto, MD, PhD\textsuperscript{a}, Eiji Tanaka, MD, PhD\textsuperscript{a}

Abstract

Although renal impairment is a frequent complication in cirrhosis that is associated with a poor prognosis, little has been reported on the clinical significance of renal impairment in cirrhosis in Japan. This retrospective study assessed the impact of renal impairment on mortality in Japanese cirrhosis patients taking conventional diuretics.

A total of 157 patients with cirrhosis receiving diuretic treatment were evaluated for the presence and status of renal impairment, defined as an increase in serum creatinine of \( \geq 0.3\text{mg/dL} \) or by \( \geq 50\% \), and then classified according to the International Club of Ascites (ICA)-Acute Kidney Injury (AKI) staging system.

Eighty of 157 (51\%) patients fulfilled the criteria for renal impairment. Thirty-four (43\%) patients had ICA-AKI stage 1, 32 (40\%) stage 2, and 14 (18\%) stage 3. Multivariate analysis revealed female gender (hazard ratio [HR] = 4.275, 95\% confidence interval = 1.962–9.312; \( P = .001 \)) as independent factors significantly increasing the risk of mortality. Cumulative survival rates increased significantly with ICA-AKI stage (log-rank test, \( P = .009 \)).

Renal impairment was a predictive marker of mortality in Japanese patients with cirrhosis. Stratification according to ICA-AKI criteria of kidney function impairment may be a good prognostic indicator of cirrhosis outcome.

Abbreviations: AKI = acute kidney injury, ALD = alcoholic liver disease, HBV = hepatitis B virus, HCC = hepatocellular carcinoma, HCV = hepatitis C virus, HR = hazard ratio, HRS = hepatorenal syndrome, ICA = International Club of Ascites, MELD = model for end-stage liver disease, NASH = non-alcoholic steatohepatitis, PBC = primary biliary cholangitis.

Keywords: cirrhosis, creatinine, prognosis, renal impairment, survival

1. Introduction

Cirrhosis is defined as the histological development of regenerative nodules surrounded by fibrous bands in response to chronic liver injury that leads to portal hypertension, end-stage liver disease, and hepatocellular carcinoma (HCC).[1,2] Occurring in 20\% of hospitalizations,[3] acute kidney injury (AKI) is a frequent complication in cirrhosis patients associated with significant mortality.[4–7] One meta-analysis reported a 6.38-fold increased risk of death in patients with AKI.[8]

Although several diagnostic systems have been established for renal impairment classification in cirrhosis,[8–10] it is difficult to precisely quantify the clinical impact of renal impairment. The International Club of Ascites (ICA) developed new criteria for AKI, defining it as an abrupt reduction in renal function in critically ill patients.[11] The ICA classified renal impairment into three grades based on a rise in serum creatinine over 48 hours accompanied with mild (stage 1) to severe (stage 3) stages of AKI. Other reports have shown that progression of AKI to higher stages was independently associated with a poor prognosis in cirrhosis in Europe and the United States,[12–13] although little is known on the clinical impact of AKI in cirrhosis patients in Japan. The objective of this study was to assess the prevalence of renal impairment in Japanese cirrhosis patients taking conventional diuretics and identify the impact of renal impairment status on mortality.

2. Methods

2.1. Subjects

A total of 157 consecutive patients with cirrhosis who had been receiving a diuretic regimen at Shinshu University Hospital between January 2003 and September 2013 were enrolled in this retrospective study. The racial background of all patients was Japanese. The protocol of this investigation was approved by the ethics committee of the Shinshu University School of Medicine in accordance with the Helsinki Declaration (No. 2712). All data were gathered in the context of standard practice from clinical patient records without the need for informed consent and were anonymized and stored in a protected database. The diagnosis of cirrhosis was based on histological examination (n = 25) and/or clinical, biochemical, and imaging findings (n = 132). No patients
were diagnosed by transient elastography. Demographic, clinical, and laboratory data as well as score for Model for End-Stage Liver Disease (MELD) were obtained for each patient at the start of diuretic treatment. MELD score was calculated as reported previously.\textsuperscript{[11]} Exclusion criteria included prior kidney disease (baseline creatinine \(>3.0\text{mg/dL}\)), acute or chronic renal replacement therapy at the time of enrollment, estimated life expectancy of less than three days, and other known causes of renal insufficiency, such as glomerulonephritis or hydropneprosis.

Clinical data contained information about hepatic edema, gastro-esophageal varices, ascites, hepatic encephalopathy, and other complications of cirrhosis. The presence of ascites was determined by ultrasonography or computed tomography. Hepatitis B surface antigen, anti-hepatitis C virus (HCV) antibody, and HCV RNA (when positive for anti-HCV antibody) were evaluated to identify persistent hepatitis B virus (HBV) or HCV infections.\textsuperscript{[17,18]} Autoimmune hepatitis\textsuperscript{[19]} and primary biliary cholangitis (PBC)\textsuperscript{[20]} were diagnosed using histological examination and serological testing, as reported previously. Alcoholic liver disease (ALD) and non-alcoholic steatohepatitis (NASH) were determined using conventional methods.

### 2.2. Definition of renal impairment

Renal impairment was defined according to the ICA–AKI criteria. AKI was considered to exist for an increase in serum creatinine of \(\geq 0.3\text{mg/dL}\) or \(\geq 50\%\) over baseline during treatment with diuretics, which was defined as the most recent stable serum creatinine value available within the 3 months preceding therapy. AKI stages were defined as follows: stage 1 = increase in serum creatinine of \(\geq 0.3\text{mg/dL}\) or increase of 1.5-fold to 2-fold from baseline; stage 2 = increase in serum creatinine of 2-fold to 3-fold from baseline; stage 3 = increase in serum creatinine of \(>3\)-fold from baseline or serum creatinine of \(\geq 4.0\text{mg/dL}\) with an acute increase of \(\geq 0.3\text{mg/dL}\) or initiation of renal replacement therapy. The diagnostic criteria of hepatorenal syndrome type (HRS)-AKI were defined using ICA criteria as previously reported.\textsuperscript{[11]}

#### 2.3. Statistical analysis

The Mann–Whitney U test was used to analyze continuous variables. Fisher’s exact and Pearson’s chi-square tests were adopted for analysis of categorical data. To identify potential factors associated with death, univariate and multivariate analyses were conducted using the Cox proportional-hazards regression model. Comparisons of renal impairment status among patients were calculated using Kaplan–Meier statistics, and differences between groups were analyzed using the log-rank test. A \(P\) value of less than .05 was considered to be statistically significant. All statistical analyses were performed using IBM SPSS statistics software version 21.0.

### 3. Results

The baseline demographic, clinical, and laboratory data of the patients included in this study are shown in Table 1. Median age was 60 years, and 45\% of subjects were male. The median follow-up periods were 522 months. The etiology of cirrhosis was hepatitis C in 59\% of patients, hepatitis B in 13\%, NASH in 9\%, ALD in 6\%, PBC in 6\%, and cryptogenic in 6\%. Complications of leg edema were present in 69\% of patients, gastro-esophageal varices in 61\%, ascites in 51\%, hepatic encephalopathy in 17\%, and spontaneous bacterial peritonitis in 1\%. With regard to diuretics, a combination of spironolactone and furosemide was given to 50\% of patients, spironolactone alone to 27\%, furosemide alone to 21\%, and others to 2\%. Interferon-based therapy and nucleo(s) tide analogs were taken by 25\% of patients.

| Table 1 | Baseline characteristics at enrollment and comparison of survival and death patients. |
|---------|-----------------------------------------------------------------------------------|
| **Baseline characteristic** | **Total n = 157** | **Survival n = 104** | **Death n = 53** | **P value** |
| Age (years) | 69 (61–76) | 68 (61–76) | 73 (63–76) | .154 |
| Male | 70 (45) | 39 (38) | 31 (59) | .012 |
| Follow-up (months) | 522 (128–1263) | 710 (311–1457) | 133 (37–601) | <.001 |
| Etiology of cirrhosis | | | | |
| Hepatitis C | 92 (59) | 60 (58) | 32 (60) | | |
| Hepatitis B | 21 (13) | 15 (14) | 6 (11) | | |
| Non-alcoholic steatohepatitis | 14 (9) | 9 (9) | 5 (9) | | |
| Alcohol liver disease | 9 (6) | 6 (6) | 3 (6) | | |
| Primary biliary cirrhosis | 9 (6) | 4 (4) | 5 (9) | | |
| Autoimmune hepatitis | 3 (2) | 3 (3) | 0 (0) | | |
| Cryptogenic | 9 (6) | 7 (7) | 2 (4) | | |
| Leg edema | 109 (69) | 72 (69) | 37 (70) | .920 |
| Gastro-esophageal varices | 95 (61) | 66 (64) | 29 (58) | .353 |
| Ascites | 80 (51) | 47 (46) | 33 (62) | .049 |
| Hepatic encephalopathy | 27 (17) | 16 (15) | 11 (21) | .399 |
| Spontaneous bacterial peritonitis | 2 (1) | 1 (1) | 1 (2) | .792 |
| MELD score | 9.8 (8.2–11.9) | 9.3 (8.1–11.5) | 10.8 (8.7–12.6) | .005 |
| Albumin (g/dL) | 3.2 (2.9–3.6) | 3.0 (2.6–3.3) | 3.3 (3.0–3.7) | .039 |
| Creatinine (mg/dL) | 0.7 (0.6–0.9) | 0.7 (0.6–0.8) | 0.7 (0.6–1.0) | .285 |
| Alanine aminotransferase (IU/L) | 55 (23–54) | 32 (21–47) | 41 (30–71) | .006 |
| Total bilirubin (mg/dL) | 1.19 (0.90–1.81) | 1.18 (0.82–1.71) | 1.28 (0.95–2.49) | .080 |
| Sodium (mEq/L) | 139 (137–141) | 140 (138–141) | 138 (136–141) | .010 |
| Platelet count (10^12/mL) | 9.1 (6.1–11.8) | 9.0 (5.9–11.9) | 9.6 (7.7–12.5) | .199 |
| International normalized ratio | 1.16 (1.08–1.25) | 1.15 (1.08–1.23) | 1.18 (1.08–1.29) | .441 |

Data are expressed as number (%) or median (first-third quartiles). MELD = model for end-stage liver disease.
with HCV and 29% with HBV. Branched-chain amino acid granules were administered to 65% of all patients. Among the 157 patients enrolled, 80 (51%) fulfilled the ICA–AKI criteria (Fig. 1). Forty-three percent of patients had stage 1, 40% had stage 2, and 18% had stage 3. Among 44 patients with renal impairment and ascites, only 3 fulfilled the ICA diagnostic criteria for HRS-AKI due to albumin treatment restrictions prior to 2014. The patients were divided into two groups according to the absence or presence of renal impairment and their clinical features at the start of diuretics compared (Table 2). Univariate analysis revealed that patients with renal impairment had a higher peak creatinine (2.0 vs 0.8 mg/dL; \( P < .001 \)), while no significant associations were detected for cirrhosis etiology or complications. The type of diuretic medication did not factor

![Figure 1. Prevalence of renal impairment in patients with cirrhosis.](image)

### Table 2
Comparison of characteristics between patients without and with renal impairment.

| Baseline characteristic | Total \( n = 157 \) | Renal impairment \((−)\) \( n = 77 \) | Renal impairment \((+)\) \( n = 80 \) | \( P \) value |
|------------------------|------------------|------------------|-----------------|-------------|
| Age (years)            | 69 (61–76)       | 69 (61–78)       | 70 (61–76)      | .611        |
| Male                   | 70 (45)          | 34 (44)          | 33 (45)         | .915        |
| Follow-up (months)     | 522 (128–1263)   | 452 (63–1057)    | 558 (156–2587)  | .194        |
| Etiology of cirrhosis  |                 |                  |                 | .572        |
| Hepatitis C            | 92 (59)          | 42 (55)          | 50 (63)         |             |
| Hepatitis B            | 21 (13)          | 14 (18)          | 7 (9)           |             |
| Non-alcoholic steatohepatitis | 14 (9) | 5 (7) | 9 (11) | |
| Alcoholic liver disease| 9 (6)            | 4 (5)            | 5 (6)           |             |
| Primary biliary cirrhosis | 9 (6) | 5 (7) | 4 (5) | |
| Autoimmune hepatitis   | 3 (2)            | 2 (3)            | 1 (1)           |             |
| Cryptogenic            | 9 (6)            | 5 (7)            | 4 (5)           |             |
| Leg edema              | 109 (69)         | 57 (74)          | 52 (67)         | .316        |
| Gastro-esophageal varices | 95 (61) | 46 (61) | 49 (61) | .926        |
| Ascites                | 80 (51)          | 36 (47)          | 44 (56)         | .264        |
| Hepatic encephalopathy | 27 (17)          | 12 (16)          | 15 (19)         | .599        |
| Spontaneous bacterial peritonitis | 2 (1) | 1 (1) | 1 (1) | .493 |
| MELD score             | 9.8 (8.2–11.9)   | 9.8 (8.2–11.8)   | 9.6 (7.9–11.9)  | .559        |
| Albumin (g/dL)         | 3.2 (2.9–3.6)    | 3.2 (2.8–3.7)    | 3.2 (3.0–3.6)   | .624        |
| Creatinine (mg/dL)     | 0.7 (0.6–0.9)    | 0.7 (0.6–0.8)    | 0.7 (0.6–0.9)   | .359        |
| Peak creatinine (mg/dL)| 1.1 (0.8–2.1)    | 0.8 (0.6–1.0)    | 2.0 (1.3–3.5)   | <.001       |
| Alanine aminotransferase (IU/L) | 35 (23–54) | 37 (23–61) | 35 (22–52) | .338 |
| Total bilirubin (mg/dL)| 1.19 (0.90–1.81) | 1.32 (0.64–2.08) | 1.12 (0.86–1.63) | .124        |
| Sodium (mEq/L)         | 130 (137–141)    | 139 (136–141)    | 140 (137–141)   | .439        |
| Platelet count (10^3/μL)| 9.1 (6.1–11.8)  | 8.9 (6.0–11.9)   | 9.4 (6.6–11.7)  | .450        |
| International normalized ratio | 1.16 (1.08–1.25) | 1.16 (1.06–1.26) | 1.16 (1.06–1.23) | .263 |

Data are expressed as number (%) or median (first-third quartiles). MELD = model for end-stage liver disease.
significantly between the renal impairment (+) and renal impairment (−) groups as well (spironolactone and furosemide: 48% vs 55%, respectively; spironolactone only: 21% vs 21%, respectively; furosemide only: 31% vs 24%, respectively).

We next focused on the effect of renal impairment status on mortality. Of the 157 patients, 53 (34%) died from liver-related causes (30 from HCC, 17 from liver failure, and 6 from bleeding esophageal varices) during the follow-up period. No patients received liver transplantation. As shown in Table 3, non-surviving patients displayed a male preponderance (59% vs 38%; \( P = .012 \)), higher incidence of ascites (62% vs 46%; \( P = .049 \)), higher MELD score (10.8 vs 9.3; \( P = .005 \)), higher alanine

![Log-rank test: \( P = 0.023 \)]

![Log-rank test: \( P = 0.009 \)]

Figure 2. Kaplan–Meier overall survival curves based on renal impairment status. (A) Survival curves of patients classified according to the presence or absence of renal impairment. (B) Survival curves of patients classified according to the absence of renal impairment and ICA–AKI stage (no renal impairment vs stage 1, \( P = .493 \); no renal impairment vs stage 2, \( P = .012 \); no renal impairment vs stage 3, \( P = .007 \); stage 1 vs stage 2, \( P = .096 \); stage 1 vs stage 3, \( P = .030 \); stage 2 vs stage 3, \( P = .26 \)).
differences in survival between patients without renal impairment and that the presence of renal impairment was an independent risk factor of mortality. Especially in patients with minimal or no alterations in serum creatinine because of reduced muscle mass.[24] Thus, clinicians should bear in mind that kidney function might already be severely impaired in cirrhosis patients whose serum creatinine surpasses the upper limit of normal and that undetected renal failure may exist even when creatinine remains within reference limits.

Recent studies have uncovered several urinary and plasma biomarkers that can predict kidney injury in patients with cirrhosis.[14,25,26] In particular, increased levels of interleukin-18, kidney injury molecule-1, liver-type fatty acid binding protein, and neutrophil gelatinase-associated lipocalin are specific indicators of structural injury rather than surrogate markers for deceased filtration. Biomarkers reflecting tubular injury have also been associated with such outcomes as worsening of renal impairment and mortality. Recently, Hayek et al.[27] reported that plasma-soluble urokinase-type plasminogen activator receptor was linked to the incidence of chronic kidney disease. We were not able to assess these biomarkers in our cohort due to a lack of urine and serum samples. Further study of additional biomarkers estimating the severity and mortality of renal impairment in cirrhosis is warranted.

We earlier proposed that serum sodium concentration could represent predictive markers of mortality in cirrhosis by Kaplan–Meier statistics.[28] However, sodium concentration did not remain an independent factor of poor prognosis, possibly due to discrepancies in follow-up period and sample number. The limitations of this study are its retrospective nature and small sample size. Moreover, the treatment standards for cirrhosis in Japan changed over the course of follow-up.

5. Conclusion

Our findings validated those of global studies on renal impairment as a predictive marker of mortality in patients with cirrhosis who are taking diuretics. Stratification based on the ICA–AKI criteria of kidney function impairment provided similarly good prognostic results, which may help improve the prognosis and disease management of patients with cirrhosis in Japan.

Acknowledgments

The authors thank Trevor Ralph for his editorial assistance.

Author contributions

Conception and design: Takeji Umemura.

Data curation: Takeji Umemura, Soichiro Shibata, Tomoo Yamazaki, Naoyuki Fujimori.

Formal analysis: Takeji Umemura, Akihiro Matsumoto.

Investigation: Takeji Umemura, Satoru Joshita, Soichiro Shibata, Tomoo Yamazaki.

Methodology: Takeji Umemura, Soichiro Shibata, Akihiro Matsumoto.

Project administration: Takeji Umemura, Eiji Tanaka.

Resources: Satoru Joshita, Soichiro Shibata, Ayumi Sugiuira, Tomoo Yamazaki, Naoyuki Fujimori.

Software: Akihiro Matsumoto.

Supervision: Eiji Tanaka.

Validation: Satoru Joshita, Akihiro Matsumoto.

Visualization: Takeji Umemura.

Writing – original draft: Takeji Umemura.

Writing – review & editing: Satoru Joshita, Eiji Tanaka. Takeji Umemura: 0000-0001-7985-919X.
References

[1] Umemura T, Ichijo T, Yoshizawa K, et al. Epidemiology of hepatocellular carcinoma in Japan. J Gastroenterol 2009;44(Suppl 19):102–7.
[2] Tsiochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet 2014;383:1749–61.
[3] Garcia-Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis. Hepatology 2008;48:2064–77.
[4] Cardenas A, Gines P, Uriz J, et al. Renal failure after upper gastrointestinal bleeding in cirrhosis: incidence, clinical course, predictive factors, and short-term prognosis. Hepatology 2001;34:671–6.
[5] Tandon P, Garcia-Tsao G. Renal dysfunction is the most important independent predictor of mortality in cirrhotic patients with spontaneous bacterial peritonitis. Clin Gastroenterol Hepatol 2011;9:260–5.
[6] Tsien CD, Rabie R, Wong F. Acute kidney injury in decompensated cirrhosis. Gut 2013;62:133–7.
[7] Belcher JM, Garcia-Tsao G, Sanyal AJ, et al. Association of AKI with mortality and complications in hospitalized patients with cirrhosis. Hepatology 2013;57:753–62.
[8] Fede G, D’Amico G, Arvaniti V, et al. Renal failure and cirrhosis: a systematic review of mortality and prognosis. J Hepatol 2012;56: 810–8.
[9] Kellum JA, Levin N, Bouman C, et al. Developing a consensus classification system for acute renal failure. Curr Opin Crit Care 2002;8:509–14.
[10] Ostermann M, Chang RW. Challenges of defining acute kidney injury. QJM 2011;104:237–43.
[11] Angeli P, Gines P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Gut 2015;64:531–7.
[12] Fagundes C, Barreto R, Guevara M, et al. A modified acute kidney injury classification for diagnosis and risk stratification of impairment of kidney function in cirrhosis. J Hepatol 2013;59:474–81.
[13] Plano S, Rosi S, Maresio G, et al. Evaluation of the acute kidney injury Network criteria in hospitalized patients with cirrhosis and ascites. J Hepatol 2013;59:482–9.
[14] Belcher JM, Sanyal AJ, Peixoto AJ, et al. Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. Hepatology 2014;60:622–32.
[15] Bucskics T, Mandonier M, Schwabl P, et al. Impact of acute kidney injury on prognosis of patients with liver cirrhosis and ascites: a retrospective cohort study. J Gastroenterol Hepatol 2015;30:1657–65.
[16] Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464–70.
[17] Umemura T, Tanaka E, Kiyosawa K, et al. Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan. Clin Infect Dis 2008;47:e52–6.
[18] Umemura T, Wang YR, Schechterly C, et al. Quantitative analysis of anti-hepatitis C virus antibody-secreting B cells in patients with chronic hepatitis C. Hepatology 2006;43:91–9.
[19] Umemura T, Zen Y, Hamano H, et al. Immunoglobulin G4-hepatopathy: association of immunoglobulin G4-bearing plasma cells in liver with autoimmune pancreatitis. Hepatology 2007;46:463–71.
[20] Umemura T, Joshita S, Ichijo T, et al. Human leukocyte antigen class II molecules confer both susceptibility and progression in Japanese patients with primary biliary cirrhosis. Hepatology 2012;55:506–11.
[21] Gines P, Schrier RW. Renal failure in cirrhosis. N Engl J Med 2009;361:1279–89.
[22] Martin-Llahi M, Guevara M, Torre A, et al. Prognostic importance of the cause of renal failure in patients with cirrhosis. Gastroenterology 2011;140:488–96, e484.
[23] Angeli P, Gines P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol 2015;62:968–74.
[24] Angeli P, Sanyal A, Moller S, et al. Current limits and future challenges in the management of renal dysfunction in patients with cirrhosis: report from the International Club of Ascites. Liver Int 2013;33:16–23.
[25] Belcher JM, Parikh CR, Garcia-Tsao G. Acute kidney injury in patients with cirrhosis: perils and promise. Clin Gastroenterol Hepatol 2013;11:1350–8.
[26] Belcher JM, Sanyal AJ, Garcia-Tsao G, et al. Early trends in cystatin C and outcomes in patients with cirrhosis and acute kidney injury. Int J Nephrol 2014;2014:708585.
[27] Hayek SS, Sever S, Ko YA, et al. Soluble urokinase receptor and chronic kidney disease. N Engl J Med 2013;373:1916–25.
[28] Umemura T, Shibata S, Sekiguchi T, et al. Serum sodium concentration is associated with increased risk of mortality in patients with compensated liver cirrhosis. Hepatol Res 2015;45:739–44.